The regulation could represent a sweeping shift in how drug prices are set in the U.S. and potentially eliminate some of the opacity that surrounds the system.
kickback protections widely blamed safe harbor protections Related: HHS secretary Azar calls for 'a system without rebates' Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.
June 03, 2026
Lifetime prices for the same drugs fell an average of 13% across 19 comparable high-income countries.
June 03, 2026
As seen during March's market decline, participants largely avoided sweeping changes despite heightened uncertainty. The April rebound shows that discipline carried forward as markets recovered.
June 03, 2026
Along with MultiPlan, the lawsuit names Aetna, Cigna, UnitedHealthcare, Humana, Elevance, Molina, Centene and Health Care Service Corp.